Samsung Bioepis announced on the 18th that it has announced the results of research on the ophthalmic disease treatment "SB11 (Lucentis biosimilar, Ranibizumab)" at the ASRS conference held in New York from the 13th to the 16th (local time).

Samsung Bioepis released the results of post-hoc analysis of phase 3 clinical data for macular degeneration patients through an oral presentation session at an academic conference on the 16th. The presentation was conducted by Neil M. Bressler, a professor at Johns Hopkins University who participated in phase 3 clinical trials of SB11.

Samsung Bioepis has conducted phase 3 clinical trials for 705 patients in 9 countries. A comparative study based on 6